ArticleHealth science reports2025
A Prospective Cross-Sectional Cohort Study on Factors Associations With Right Heart Thrombi and Pulmonary Embolism.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction/Objective: Floating thrombus of the right heart chambers is an uncommon diagnosis and is systematically associated with pulmonary embolism. The aim of this study is to describe the management and evolution of right intracavitary thrombi (TIC) in pulmonary embolism. Materials and Method: This was a prospective cohort that ran for 76 months from March 5, 2017 to July 31, 2023. Patients diagnosed with pulmonary embolism were included. Two population groups were established according to the presence or absence of right intracavitary thrombus on Doppler echocardiography (intracavitary thrombi+ vs. intracavitary thrombi-) permitted to compare the risks factors. Thromboembolic risk factors, including the patient's background and clinical, paraclinical, therapeutic and evolutionary aspects, were reported. A significance level of Results: The prevalence of emboli associated with intracavitary thrombi was 2.98%. Arterial hypotension, right ventricular dilatation, and deaths were significantly associated with right chamber thrombi with Conclusion: The discovery of a thrombus of the right heart, although rare, is not exceptional. Their management is the subject of controversy between learned societies. Thrombolysis is the only therapeutic option in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.